Pro

Ruth Gallily, PhD, Berthan and Max Densen Professor Emerita of Immunology at the Hebrew University of Jersualem, et al., wrote in their July 20, 2010 approved patent application #7759526 "Pharmaceutical Compositions Comprising Cannabidiol Derivatives" available on the website patentgenius.com:

“The present invention relates to cannabidiol… and to pharmaceutical compositions comprising cannabidiol… being anti-inflammatory agents having analgesic, antianxiety, anticonvulsive, neuroprotective, antipsychotic andanticancer activity…

CBD… has been shown in in vitro assays, in animal tests, as well as in some human, preliminary trials, to produce numerous pharmacological effects… which are of potential therapeutic value… [R]ecent reports describe the in vitro effects of CBD on immune cells… These in vitro studies lend support to earlier reports on analgesic and anti-inflammatory effects in animals…

CBD has been found to produce several, potentially therapeutic, effects in animal models, as well as in patients with neurological diseases… in anxiety… and in psychosis… CBD is a neuroprotective antioxidant.”

July 20, 2010